September 12, 2018
September 9, 2018
The Canadian Ministry of Health has invited public comment on marketing statements that it proposes to allow e-cigarette companies to make to seel their wares.
The big problem is that these claims ignore everything we have learned about the dangers and use patterns of e-cigarettes in the last year or so.
Here is the comment I sent in. You can download a PDF of it here.
September 11, 2018
Mathew Cook
Manager, Regulations Division
Tobacco Products Regulatory Office
Tobacco Control Directorate
RE: Authorized statements regarding e-cigarettes
Dear Mr. Cook,
It has come to my attention that you are seeking comments on the List of Statements for Use in the Promotion of Vaping Products. I am pleased to offer some comments on these statements.
September 6, 2018
The tobacco companies have been going around the state telling people that San Francisco is not enforcing its comprehensive ban on the prohibition on the sale of flavored tobacco products.
The San Francisco Department of Public Health has proven them wrong. The Department just updated its website with details on the implementation plan, including, sending a mailer (below) to every retailer in the City telling them that the law is in effect and that they should stop ordering flavored products.
Here is the schedule that the City has announced:
July 20, 2018 Ban effective date
Sep 2018 Outreach and Education On-Site-Visits Begin
Oct 2018 Compliance Inspections Begin
Jan 2019 Enforcement Begins After Rules and Regulations are Adopted.
The Department is beginning with outreach to the tobacco retailers educating them on the flavored tobacco products ban, collecting questions they may have concerning flavored tobacco products and answering them.
August 31, 2018
August 30, 2018
Karma KcKelvey and colleagues’ paper “IQOS labelling will mislead consumers” presents the results of a close analysis of the information on consumer perceptions of IQOS that PMI presents in its modified risk tobacco product (MRTP) application to the FDA to market IQOS as a reduced risk and reduced exposure product. They conclude that PMI’s studies did not provide sufficient evidence that IQOS users will completely switch from cigarettes to IOQS (the assumed behavior that the whole application hinges on) or that consumers will understand PMI’s proposed claims regarding exposure, harm and “switching completely.” They go on to conclude that PMI’s MRTP application does not satisfy FDA requirements that consumers will not be misled by PMI’s proposed marketing; therefore, HTP should not be allowed to be marketed with reduced risk claims.